Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Stress signaling etches heritable marks on chromatin.
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial.
Disease-modifying treatments for progressive multiple sclerosis.
Prevention and treatment of MS: studying the effects of vitamin D.
Early relapses, onset of progression, and late outcome in multiple sclerosis.
Fingolimod phosphate promotes the neuroprotective effects of microglia.
A systematic review of research undertaken in vocational rehabilitation for people with multiple sclerosis.
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
The history of the oxazaphosphorine cytostatics.
Expression and activation by epstein barr virus of human endogenous retroviruses-w in blood cells and astrocytes: inference for multiple sclerosis.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
Value and Efficacy of Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical Review Since 2000.
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
Meanings, motivations, and strategies for engaging in physical activity among women with multiple sclerosis.
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Fingolimod modulates microglial activation to augment markers of remyelination.
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.

Pages